Ha Tay Pharmaceutical JSC (HNX:DHT)
Vietnam · Delayed Price · Currency is VND 49,900
+1,000 (2.04%)
At close: Nov 3, 2026
Ha Tay Pharmaceutical JSC Ratios and Metrics
Market cap in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,971,609 | 6,340,200 | 7,822,325 | 1,893,826 | 1,027,245 | 1,188,329 | |
Market Cap Growth | -28.06% | -18.95% | 313.04% | 84.36% | -13.56% | 5.54% |
Enterprise Value | 5,024,541 | 6,536,629 | 8,043,089 | 2,176,376 | 1,099,907 | 1,060,741 |
Last Close Price | 48900.00 | 63636.36 | 78512.40 | 18487.72 | 11167.27 | 12305.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 143.40 | 118.16 | 108.99 | 22.27 | 10.79 | 17.49 |
PS Ratio | 2.05 | 2.64 | 3.75 | 0.95 | 0.56 | 0.74 |
PB Ratio | 4.29 | 5.71 | 7.40 | 1.78 | 1.29 | 1.58 |
P/TBV Ratio | 4.40 | 5.86 | 7.61 | 1.83 | 1.33 | 1.63 |
P/FCF Ratio | 37.85 | 35.83 | - | - | - | - |
P/OCF Ratio | 31.70 | 28.09 | 279.78 | 6.99 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.07 | 2.72 | 3.86 | 1.09 | 0.60 | 0.66 |
EV/EBITDA Ratio | 94.76 | 100.79 | 82.92 | 18.71 | 9.17 | 13.48 |
EV/EBIT Ratio | - | 160.56 | 105.12 | 21.94 | 10.74 | 17.09 |
EV/FCF Ratio | 38.26 | 36.94 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.21 | 0.30 | 0.45 | 0.47 | 0.42 | 0.38 |
Debt / EBITDA Ratio | 4.90 | 5.14 | 4.85 | 4.33 | 2.81 | 3.68 |
Debt / FCF Ratio | 1.89 | 1.88 | - | - | - | - |
Net Debt / Equity Ratio | 0.02 | 0.09 | 0.27 | 0.11 | 0.23 | -0.18 |
Net Debt / EBITDA Ratio | 0.52 | 1.52 | 2.99 | 1.05 | 1.53 | -1.69 |
Net Debt / FCF Ratio | 0.20 | 0.56 | -2.52 | -1.27 | -0.64 | 1.59 |
Asset Turnover | 1.28 | 1.25 | 1.11 | 1.21 | 1.36 | 1.49 |
Inventory Turnover | 4.89 | 4.21 | 4.12 | 4.28 | 4.12 | 4.08 |
Quick Ratio | 0.70 | 0.47 | 0.40 | 0.81 | 0.47 | 1.18 |
Current Ratio | 1.42 | 1.22 | 1.21 | 1.69 | 1.80 | 2.10 |
Return on Equity (ROE) | 3.26% | 5.45% | 7.08% | 9.54% | 12.75% | 12.95% |
Return on Assets (ROA) | 0.40% | 1.32% | 2.54% | 3.75% | 4.73% | 3.60% |
Return on Invested Capital (ROIC) | 0.75% | 2.56% | 4.76% | 7.37% | 10.27% | 9.03% |
Return on Capital Employed (ROCE) | 1.00% | 3.40% | 6.60% | 8.00% | 11.30% | 8.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.70% | 0.85% | 0.92% | 4.49% | 9.27% | 5.72% |
FCF Yield | 2.64% | 2.79% | -1.47% | -5.05% | -27.84% | -7.05% |
Dividend Yield | 1.66% | - | - | - | 2.57% | 2.22% |
Payout Ratio | - | - | 111.73% | - | 53.87% | 29.96% |
Buyback Yield / Dilution | - | 8.17% | -62.83% | 31.61% | -0.77% | 0.77% |
Total Shareholder Return | 1.69% | 8.17% | -62.83% | 31.61% | 1.80% | 2.99% |